Clinical Trials Sponsored by Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Total 4606 results

Zhejiang Cancer Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

Female Breast Cancer Patients | Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer | HRD Positive Advanced Breast Cancer
Yantai Yuhuangding Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer

Breast Cancer

China
Jinling Hospital, China
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Adbelizumab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer

Pancreatic Cancer | Neoadjuvant Therapy

China
Wuhan Union Hospital, China
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA

Aplastic Anemia | Primary Immune Thrombocytopenia

China
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Nasopharyngeal Carcinoma

China
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

Metastatic Biliary Tract Cancer | Locally Advanced Biliary Tract Cancer

China
Zhongshan Hospital Xiamen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study

Stage IV Gastric Cancer With Metastasis
Wuhan Union Hospital, China
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients

Primary Immune Thrombocytopenia
Peking University People's Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Enrolling by invitation

Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer

Germline BRCA-mutated HER2-negative Breast Cancer

China
Fujian Cancer Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.; SunWay Biotech Co., LTD.

Not yet recruiting

Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma

Liver Metastases | Malignant Melanoma
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic Sarcoma

Sarcoma

China
Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Completed

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants

Lymphoma, Non-Hodgkin

United States
Jiangsu HengRui Medicine Co., Ltd.
Atridia Pty Ltd.

Recruiting

A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors

Advanced Solid Tumors

China, Korea, Republic of, Taiwan, United States, Australia
Peking University First Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.; Beijing Biote Pharmaceutical Co.,Ltd

Recruiting

Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma

Salivary Gland Neoplasm Duct

China
Jiangsu Cancer Institute & Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma
RenJi Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid Leukemia (H-CIT-AML)

Chemotherapy-Induced Thrombocytopenia
Peking University
Jiangsu HengRui Medicine Co., Ltd.

Completed

Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Peking University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer

Gastric Cancer

China
Fudan University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib in the Treatment of Metastatic Colorectal Cancer

Colorectal Cancer

China
Fudan University
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer

Breast Neoplasms

China
Fudan University
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer

Breast Neoplasms

China
Fudan University
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Exploratory Clinical Study of HRS-4642 Combined With Adebelimab in the Treatment of Advanced Pancreatic Cancer

Pancreatic Cancer

China
Shengjing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in ER Positive/HER2 Low Breast Cancer

ER Positive/HER2 Low Breast Cancer

China
Shengjing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR-A1811 Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

HER2-positive Breast Cancer

China
Peking University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

China
Ruijin Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.

Breast Cancer | HER2-positive Breast Cancer | ER-positive Breast Cancer
Fudan University
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients

Metastatic Breast Cancer

China
Peking University Cancer Hospital & Institute
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor

Cldn18.2-positive Advanced Solid Tumor

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical Trial

Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

High-risk Non-muscle Invasive Bladder Cancer

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma

B-cell Non-Hodgkin's Lymphoma

China
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）

Eosinophilic Granulomatosis With Polyangiitis

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Trial of SHR-7367 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A First-in-human Study of HRS2398 Tablets in Subjects With Advanced Malignant Tumors

Advanced Malignant Tumor

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Study of HRS2543 in Patients With Advanced Tumors

Advanced Tumors

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer

ER-Positive, HER2-Negative Breast Cancer

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Trial of SHR-1905 in Healthy Subjects and Subjects With Mild Asthma

Asthma

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Enrolling by invitation

A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis

Moderate to Severe Atopic Dermatitis

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Completed

A Study of SHR-1707 in Healthy Young Adult and Elderly Subjects

Alzheimer's Disease

China
Guangdong Hengrui Pharmaceutical Co., Ltd

Completed

A Trial of HRS-2261 in Healthy Subjects After Single and Multiple Oral Administration

Chronic Cough

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Completed

A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Children

Preoperative Sedation of Children

China
Guangdong Hengrui Pharmaceutical Co., Ltd

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-4597 Inhalation in Healthy Subjects and Asthmatic Patients

Healthy Subjects | Asthmatic Patients
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

A Phase I Study of SHR -2001 in Healthy Subjects

Healthy

China
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps

Chronic Rhinosinusitis With Nasal Polyps

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

Safety, Tolerability and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients.

Alzheimer's Disease

China
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

Study on Single and Multiple Atomization Inhalation of HRS-9821 Suspension for Inhalation in Healthy Subjects

Chronic Obstructive Pulmonary Disease

China

Clinical Trials Sponsored by Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations